



February 5, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

**“Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility
at Chestnut Ridge, New York**

**Inspection included Drug Device Combinations
covering our recent filing in Nasal Sprays domain”**

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No. A30515

Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

Tel: +91-80-6784 0000 **Fax:** +91 80 6784 0700

Regd Off: 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

Tel: +91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com



Press Release

February 5, 2026

Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New York

Inspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain

Bangalore, India, February 5, 2026 - Strides Pharma Science Limited (Strides) today announced that Strides Pharma Inc. (SPI), a step-down wholly owned subsidiary of the Company in the USA, has received the USFDA Inspection Closure Report (Establishment Inspection Report – EIR) for its Formulations Facility located at Chestnut Ridge, New York, USA.

The Facility was inspected by the United States Food and Drug Administration (USFDA) from December 17, 2025 to December 23, 2025. The inspection covered current Good Manufacturing Practices (cGMP) and included a pre-approval inspection for Drug-Device Combination capabilities, covering the Company's recent filing in Nasal Sprays domain.

Based on SPI's response to the Form 483 that was issued at the conclusion of the inspection, the USFDA has classified the inspection outcome as VAI (Voluntary Action Indicated). The EIR states that the inspection has been closed.

The Chestnut Ridge facility caters to the U.S. market and manufactures Liquids, Gels, Hormones, Modified Release products and Controlled Substances, supporting several current and future products for the U.S. market. The successful closure of this inspection including Device Combinations further strengthens the Company's U.S. business and near term growth prospects.

Strides remains committed to the highest standards of regulatory compliance and will continue to focus on the manufacture of high-quality pharmaceutical products for global markets.

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

For further information, please contact:

<p><u>Institutional Investors</u></p> <p>Vikesh Kumar Group CFO investor-relations@strides.com</p> <p>Saurabh Ambaselkar Investor Relations +91 99609 31220 saurabh.ambaselkar@strides.com</p> <p><u>Strides Pharma Science Limited</u> CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560 076</p>	<p><u>Corporate Communication</u></p> <p>Pallavi Panchmatia: +91 80 6784 0193 Pallavi.panchmatia@strides.com</p> <p><u>PR Consultancy</u></p> <p>Adfactors PR</p> <p>Janhavi Bellare: +91 93228 54508 Janhavi.bellare@adfactorspr.com</p> <p>Talal Syed: +91 99876 19679 syed.talal@adfactorspr.com</p>
--	---